Osimertinib Treatment Based on Plasma T790M Monitoring in Patients With EGFR-Mutant NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
Ann. Oncol 2023 Feb 28;[EPub Ahead of Print], J Remon, B Besse, SP Aix, A Callejo, K Al-Rabi, R Bernabe, L Greillier, M Majem, N Reguart, I Monnet, S Cousin, P Garrido, G Robinet, RG Campelo, A Madroszyk, J Mazières, H Curcio, B Wasąg, Y Pretzenbacher, B Fournier, AC Dingemans, R DziadziuszkoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.